沃森生物(300142.SZ)：子公司收到13价肺炎球菌多糖结合疫苗约旦药品注册证

Core Viewpoint - Watson Bio's subsidiary, Yuxi Watson Biotechnology Co., Ltd., has received a drug registration certificate for its 13-valent pneumococcal polysaccharide conjugate vaccine from the Jordan Food and Drug Administration, marking a significant step in the company's strategic expansion into the Middle East market [1] Group 1 - The receipt of the drug registration certificate signifies a key advancement in the company's internationalization efforts for its vaccine [1] - This is the first time the company's product has gained market access in Jordan, indicating potential for future sales [1] - There remains uncertainty regarding the actual market launch date and sales performance of the vaccine [1] Group 2 - The company will actively promote subsequent related work and fulfill its information disclosure obligations in a timely manner [1]